John D Horowitz1, Raffaele De Caterina2, Tamila Heresztyn3, John H Alexander4, Ulrika Andersson5, Renato D Lopes4, Philippe Gabriel Steg6, Elaine M Hylek7, Puneet Mohan8, Michael Hanna8, Petr Jansky9, Christopher B Granger4, Lars Wallentin10. 1. Cardiology Unit, Basil Hetzel Institute, Queen Elizabeth Hospital, University of Adelaide, Adelaide, South Australia, Australia. Electronic address: john.horowitz@adelaide.edu.au. 2. G. d'Annunzio University, Chieti, Italy; G. Monasterio Foundation, Pisa, Italy. 3. Cardiology Unit, Basil Hetzel Institute, Queen Elizabeth Hospital, University of Adelaide, Adelaide, South Australia, Australia. 4. Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina. 5. Uppsala Clinical Research Center, Uppsala, Sweden. 6. INSERM-Unité 698, Paris, France; Assistance Publique-Hôpitaux de Paris, Paris, France; Département Hospitalo-Universitaire FIRE, Hôpital Bichat, Paris, France; Université Paris-Diderot, Sorbonne-Paris Cité, Paris, France; NHLI Imperial College, ICMS, Royal Brompton Hospital, London, United Kingdom. 7. Boston University Medical Center, Boston, Massachusetts. 8. Bristol-Myers Squibb, Princeton, New Jersey. 9. Cardiovascular Centre, University Hospital Motol, Prague, Czech Republic. 10. Uppsala Clinical Research Center, Uppsala, Sweden; Department of Medical Sciences, Cardiology, Uppsala University, Uppsala, Sweden.
Abstract
BACKGROUND: There is little mechanistic information on factors predisposing atrial fibrillation (AF) patients to thromboembolism or bleeding, but generation of nitric oxide (NO) might theoretically contribute to both. OBJECTIVES: The authors tested the hypothesis that plasma levels of the methylated arginine derivatives asymmetric and symmetric dimethylarginine (ADMA/SDMA), which inhibit NO generation, might be associated with outcomes in AF. METHODS: Plasma samples were obtained from 5,004 patients with AF at randomization towarfarin or apixaban in the ARISTOTLE (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation) trial. ADMA and SDMA concentrations were measured by high-performance liquid chromatography. Relationships to clinical characteristics were evaluated by multivariable analyses. Associations with major outcomes, during a median of 1.9 years follow-up, were evaluated by adjusted Cox proportional hazards models. RESULTS: Both ADMA and SDMA plasma concentrations at study entry increased significantly with patients' age, female sex, renal impairment, permanent AF, or congestive heart failure. ADMA and SDMA increased (p < 0.001) with both increased CHA2DS2-VASc and HAS-BLED scores, but decreased in the presence of diabetes. On multivariable analysis adjusting for established risk factors and treatment, tertile groups of ADMA concentrations were significantly associated with stroke/systemic embolism (p = 0.034), and death (p < 0.0001), whereas tertile groups of SDMA were associated with major bleeding and death (p < 0.001 for both). Incorporating ADMA and SDMA into CHA2DS2-VASc or HAS-BLED predictive models improved C-indices for those outcomes. Neither ADMA nor SDMA predicted differential responses to warfarin or apixaban. CONCLUSIONS: In anticoagulated patients with AF, elevated ADMA levels are weakly associated with thromboembolic events, elevated SDMA levels with bleeding events and both are strongly associated with increased mortality. These findings suggest that disturbances of NO function modulate both thrombotic and hemorrhagic risk in anticoagulated patients with AF. (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation [ARISTOTLE]; NCT00412984).
RCT Entities:
BACKGROUND: There is little mechanistic information on factors predisposing atrial fibrillation (AF) patients to thromboembolism or bleeding, but generation of nitric oxide (NO) might theoretically contribute to both. OBJECTIVES: The authors tested the hypothesis that plasma levels of the methylated arginine derivatives asymmetric and symmetric dimethylarginine (ADMA/SDMA), which inhibit NO generation, might be associated with outcomes in AF. METHODS: Plasma samples were obtained from 5,004 patients with AF at randomization to warfarin or apixaban in the ARISTOTLE (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation) trial. ADMA and SDMA concentrations were measured by high-performance liquid chromatography. Relationships to clinical characteristics were evaluated by multivariable analyses. Associations with major outcomes, during a median of 1.9 years follow-up, were evaluated by adjusted Cox proportional hazards models. RESULTS: Both ADMA and SDMA plasma concentrations at study entry increased significantly with patients' age, female sex, renal impairment, permanent AF, or congestive heart failure. ADMA and SDMA increased (p < 0.001) with both increased CHA2DS2-VASc and HAS-BLED scores, but decreased in the presence of diabetes. On multivariable analysis adjusting for established risk factors and treatment, tertile groups of ADMA concentrations were significantly associated with stroke/systemic embolism (p = 0.034), and death (p < 0.0001), whereas tertile groups of SDMA were associated with major bleeding and death (p < 0.001 for both). Incorporating ADMA and SDMA into CHA2DS2-VASc or HAS-BLED predictive models improved C-indices for those outcomes. Neither ADMA nor SDMA predicted differential responses to warfarin or apixaban. CONCLUSIONS: In anticoagulated patients with AF, elevated ADMA levels are weakly associated with thromboembolic events, elevated SDMA levels with bleeding events and both are strongly associated with increased mortality. These findings suggest that disturbances of NO function modulate both thrombotic and hemorrhagic risk in anticoagulated patients with AF. (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation [ARISTOTLE]; NCT00412984).
Authors: Leticia Goni; Cristina Razquin; Estefanía Toledo; Marta Guasch-Ferré; Clary B Clish; Nancy Babio; Clemens Wittenbecher; Alessandro Atzeni; Jun Li; Liming Liang; Courtney Dennis; Ángel Alonso-Gómez; Montserrat Fitó; Dolores Corella; Enrique Gómez-Gracia; Ramón Estruch; Miquel Fiol; Jose Lapetra; Lluis Serra-Majem; Emilio Ros; Fernando Arós; Jordi Salas-Salvadó; Frank B Hu; Miguel A Martínez-González; Miguel Ruiz-Canela Journal: Am J Clin Nutr Date: 2022-09-02 Impact factor: 8.472
Authors: Achim Leo Burger; Stefan Stojkovic; André Diedrich; Svitlana Demyanets; Johann Wojta; Thomas Pezawas Journal: Clin Biochem Date: 2020-06-04 Impact factor: 3.625
Authors: A Gundlund; Thomas Kümler; Anders Nissen Bonde; Jawad Haider Butt; Gunnar Hilmar Gislason; Christian Torp-Pedersen; Lars Køber; Jonas Bjerring Olesen; Emil Loldrup Fosbøl Journal: BMJ Open Date: 2019-09-20 Impact factor: 2.692
Authors: Chiara Volani; Johannes Rainer; Vinicius Veri Hernandes; Viviana Meraviglia; Peter Paul Pramstaller; Sigurður Vidir Smárason; Giulio Pompilio; Michela Casella; Elena Sommariva; Giuseppe Paglia; Alessandra Rossini Journal: Metabolites Date: 2021-03-25